The Vetr community last Friday upgraded Teva Pharmaceuticals Ltd. (ADR) ADR TEVA from 4 stars (Buy) to 4.5 stars (Strong Buy). Crowd confidence was very bullish, with 82.6 percent of the Vetr community giving the stock a buy rating and 17.4 percent a Sell.
See how crowdsourced ratings could help you time the market
This upgrade came despite news that Teva failed to meet endpoints in a late-stage asthma study, though there was little price movement at market close. The Vetr crowd remained bullish with a target price of $23.94 compared to the current share price of $20.98, implying a 13.93 percent upside.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.